DW4421-2

Phase 1Small molecule

Daewon Pharmaceutical Co., Ltd.

DW4421-2 is one of 54 small molecule programs targeting Interaction. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InteractionNot yet recruiting

InteractionPhase 1

Not yet recruiting

Competition

Competitive Landscape

60 competitors in Interaction

#DrugCompanyPhaseTrials

Versed

CConrado Roberto Hoffmann Filho

Approved

90 2

Estrace

Novo Nordisk

Approved

2 3

Robitussin

Pfizer

Phase 3

10 4

Epsom Salt

FFresenius Kabi USA, LLC

Approved

1 5

Rifadin

Sanofi

Phase 2

33 6

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 2

75 7

Rifampicin

Boehringer Ingelheim

Phase 3

22 8

Crestor

AstraZeneca

Phase 1

60 9

Lanoxin

Tegretol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Interaction1 trial

Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin

Not yet recruiting· Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.·Phase 1·NCT07382661·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DW4421-2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DW4421-2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DW4421-2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daewon Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Daewon Pharmaceutical Co., Ltd.

DW4421-2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Interaction1 trial

References

Drug Info

Quick Facts

Related News